It has been reported that the expression of miR-16, miR-155 and miR-142-3p was upregulated in CD8+ T cells from MS patients by targeting FOXP3, interferon regulatory factor 2 binding protein 2 (IRF2BP2) and FOXO1, respectively (124). This evidence concerns the gene CD8A and myeloid sarcoma.